[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pd---parkinsons-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pd---parkinsons-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,50,74,99,128,164,187,214,239,260,285,307],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100645251","automated-daytime-adaptive-deep-brain-stimulation-parameter-optimization-in-patients-implanted-with-percept-neurostimulator-100645251",false,"NCT07682311","Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator","Auto aDBS","Inclusion Criteria:\n\n1. Age 25-75.\n2. Diagnosis of idiopathic PD.\n3. Patient has undergone surgical intervention with deep brain stimulation (Percept device) for their disorder at least 2 months prior to recruitment.\n4. Absence of significant cognitive impairment (score of 24 or greater on the Montreal Cognitive Assessment (MoCA)).\n5. Signed informed consent.\n6. Ability to comply with study follow-up visits for brain recording, testing of adaptive stimulation, and clinical assessment.\n7. Patient has been on cDBS for at least two months and still experiences significant residual motor fluctuation while on cDBS. Consequently, patient is undergoing aDBS treatment currently or was recommended aDBS as part of clinical care to manage their residual motor fluctuation.\n8. Has available cDBS Timeline LFP and stimulation data lasting at least 1 day.\n9. To be enrolled in the clinical trial phase of the study, patient will need to consent to reverting back to their baseline cDBS settings for all required cDBS testings.\n\nExclusion Criteria:\n\n1. Patient meets criteria for a psychogenic movement disorder.\n2. Significant untreated depression (BDI-II score \\>20). History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS).\n3. Any personality or mood symptoms that study personnel believe will interfere with study requirements.","ALL","25 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Parkinson's disease (PD) affects \\~1% of people over 60 years old, is highly disabling and represents a large economic burden. While dopaminergic medications effectively treat motor symptoms early in the disease, most patients develop complications, including motor fluctuations and dyskinesias, which can be partially managed by deep brain stimulation (DBS). This surgical therapy consists of delivering continuous electrical stimulation through electrodes permanently implanted in basal ganglia nuclei, with a pulse generator and battery unit implanted in the chest. However, conventional DBS therapy is delivered with constant stimulation parameters, referred to as constant deep brain stimulation (cDBS), that are unresponsive to patient activities or to variations in the severity of symptoms during daily life. This leaves many patients under- or over-stimulated during parts of the day.\n\nTo address the shortcomings of cDBS, adaptive DBS (aDBS) uses real-time detection of neural signals to automatically adjust stimulation amplitude or other parameters in response to patients' dynamic clinical needs. aDBS was approved by the U.S. Food and Drugs Administration (FDA) for clinical treatment of PD in the Percept PC and RC (Medtronic) device in February 2025.\n\nFully leveraging this therapy in the real world is limited by technical challenges, in particular the fact that: while the investigators developed a consistent pipeline for implementing aDBS, there were several critical control parameters that strongly influenced algorithm performance and required prolonged trial-and-error based testing, to achieve successful control. In this new study, the investigators seek to significantly extend this work and address the major barriers to widespread, easy adoption of aDBS by groups without specialized knowledge of neurophysiology or feedback control. Here the investigators aim to test an automated, data-driven pipeline for the recommendation of the adaptive control parameters.",[27],"PD - Parkinson's Disease",[29,30,31,32,33,34,35,36],"DBS","adaptive","aDBS","adaptive deep brain stimulation","Medtronic Percept","Parkinson's Disease","PD","Percept","RECRUITING","2026-06-26",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2032-05",{"name":47,"class":48},"University of California, San Francisco","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100623555","simplified-scalable-24-hour-adaptive-dbs-in-parkinsons-disease-100623555","NCT07398157","Simplified, Scalable, 24-hour Adaptive DBS in Parkinson's Disease","Subgaleal Cortical Electrodes in Patients With Parkinson's Disease Undergoing Deep-brain Stimulation Therapy for Sensing and Adaptive Deep-brain Stimulation Over a 24-hour Period.","Subgaleal aDBS","Inclusion criteria\n\n1. Age 25-75.\n2. Diagnosis of idiopathic PD.\n3. Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist (Dr. Bledsoe).\n4. Patient has requested surgical intervention with deep brain stimulation for their disorder or previous enrollment in sponsored IDE (G220241) to use Percept PC wired to subgaleal sensing, if patients have ongoing daytime fluctuations or sleep dysfunction despite cDBS optimization.\n5. Normal preoperative brain MRI.\n6. Absence of significant cognitive impairment (score of 24 or greater on the Montreal Cognitive Assessment (MoCA).\n7. Signed informed consent.\n8. Motor UPDRS-III off medication score 25 to 65 and a \\>35% improvement with levodopa, predominant rigid\u002Fbradykinetic symptoms (ratio of off-medication UPDRS-III limb rigidity\u002Fbradykinesia scores to limb tremor scores of \\>1.2).\n9. Motor fluctuations despite optimized medical therapy with at least 2 hours per day of either \"off\" time, or \"on\" with dyskinesias.\n10. Ability to comply with study follow-up visits for brain recording, testing of closed-loop stimulation, and clinical assessment.\n\nExclusion criteria\n\n1. Coagulopathy, uncontrolled hypertension, heart disease, or other medical condition considered to place the patient at elevated risk for surgical complications.\n2. Patient meets criteria for a psychogenic movement disorder.\n3. Pregnancy: all women of childbearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.\n4. Significant untreated depression (BDI-II score \\>20) History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS).\n5. Any personality or mood symptoms that study personnel believe will interfere with study requirements.\n6. Patient who requires electroconvulsive therapy, repetitive transcranial magnetic stimulation, or diathermy, implanted neurostimulators and MR-incompatible metallic implants, previous craniotomy on the side of the intended subgaleal implant, and drug or alcohol abuse.\n7. Patients who experience adverse effects that are undesirable and detrimental to the health of subjects from DBS or other similar neurostimulators","18 Years",{"count":60,"type":21},24,[24],"The purpose of this study is to test a new way to treat Parkinson's disease (PD). Subjects will be implanted with deep brain stimulator (DBS) devices and electrodes placed under the scalp.\n\nThe main questions it aims to answer are:\n\n* Is there a less invasive method to collect useful brain signals? Find out if these brain signals can be related to movement and\u002For sleep symptoms.\n* How to use these brain signals to tailor adaptive deep brain stimulation settings for movement and\u002For sleep symptoms\n\nResearchers will compare study derived adaptive DBS settings to subject's clinically programmed continuous DBS settings to see which is better at treating patients PD symptoms.",[27],[65,30,29],"Subgaleal","2026-04-29",{"date":68,"type":41},"2026-05-05",{"date":70,"type":41},"2026-04-09",{"date":72,"type":21},"2031-11-30",{"name":47,"class":48},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":49},"100633088","home-based-self-exercise-in-patients-with-parkinsons-disease-a-feasibility-study-100633088","NCT07522138","Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study","SelfExPD","Inclusion Criteria:\n\n* Adults aged 19 years or older, clinically diagnosed with Idiopathic Parkinson's Disease (PD) according to the Movement Disorder Society (MDS) clinical diagnostic criteria\n* Patients at Hoehn and Yahr stage 1-2.5\n* Patients on stable dopaminergic therapy with no changes in the past 1 month\n* Patients receiving Lee Silverman Voice Treatment (LSVT) rehabilitation therapy once weekly as outpatients\n* Patients who have voluntarily provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients diagnosed with atypical parkinsonism\n* Patients with musculoskeletal problems that make participation in rehabilitation difficult\n* Patients who have limited access to the video-based home exercise feedback program","19 Years",{"count":83,"type":21},15,[24],"This study aims to test whether patients with Parkinson's disease can safely and effectively use a home-based exercise program guided by videos. Participants will follow video instructions for exercises at home while their movements are monitored by a camera, which provides real-time feedback. The study will check how well participants complete the exercises, their satisfaction with the program, and any changes in clinical function. The goal is to see if this type of home exercise can help patients increase their activity levels without significant side effects.",[87,27,88],"Home Exercise Program","Feasibility Studies","NOT_YET_RECRUITING","2026-04-12",{"date":92,"type":41},"2026-04-15",{"date":94,"type":21},"2026-04-20",{"date":96,"type":21},"2027-02-28",{"name":98,"class":48},"Seoul National University Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":127},"100612215","subthalamic-nucleus-versus-globus-pallidal-internus-deep-brain-stimulation-for-parkinson-disease-100612215","NCT07250685","Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease","Superior PD","Inclusion Criteria:\n\n1. Age at the time of enrollment: 22-75 years.\n2. Diagnosis of bilateral idiopathic PD with the presence of at least 2 of the following: resting tremor, rigidity, or bradykinesia\n3. Duration of idiopathic PD: ≥ 5 years.\n4. Severity of PD in the meds off condition: Hoehn-Yahr stages 2.5\\~ 4.0.\n5. Despite optimal medication treatment, there are still persistent symptoms or drug side effects of disabling Parkinson's\n6. Must have tried a form of carbidopa\u002Flevodopa and\u002For one of the dopamine agonists as part of medication therapy.\n7. Anti-parkinsonian medications must improve PD symptoms by ≥33%, as measured by UPDRS-III score.\n8. UPDRS-III score of ≥ 30 in the meds off condition.\n9. The MMSE assessment was higher than the demarcation score of the corresponding educational level, and the cognitive function was normal.\n10. HAMD score≤24.\n11. No change in antidepressant medications utilized for treatment of depression for at least 8 weeks prior to informed consent.\n12. Stable on anti-parkinsonian medication for 28 days prior to informed consent.\n13. Could tolerate bilateral STN DBS and bilateral GPi DBS.\n14. Be willing and able to comply with all visits and study related procedures (e.g., using the remote control, charging system and completing the PD Diary\n15. Able to understand the study requirements and the treatment procedures and provides written informed consent before any studyspecific tests or procedures are performed.\n\nExclusion Criteria:\n\n1. Any intracranial abnormalities or medical conditions that Lead to the prohibition of DBS surgery.\n2. Have any significant psychiatric condition likely to compromise the subject's ability to comply with requirements of the study protocol (e.g. bipolar, schizophrenia, mood disorder with psychotic features, cluster B personality disorders).\n3. HAMD score\\>24.\n4. Any current drug or alcohol abuse, per DSM-IV criteria\n5. Any history of recurrent or unprovoked seizures.\n6. Any history of hemorrhagic stroke.\n7. Any previous treatment for movement disorders involving intracranial surgery or device implantation.\n8. Any other active implanted devices including neurostimulators (e.g., cochlear implant, pacemaker) and \u002For drug delivery pumps, whether turned on or off. Passive implants (e.g., knee prostheses) would be allowed provided that they do not interfere with the functioning of the DBS system\n9. Any previous thalamotomy, pallidotomy or subjects who have undergone a DBS procedure.\n10. Any previously implanted Vagus Nerve Stimulation (VNS) patients.\n11. Any previous brain surgery that would interfere with the placement of the leads or the functioning of the device.\n12. A condition requiring or likely to require the use of Magnetic Resonance Imaging (MRI), diathermy or electroconvulsive therapy (ECT)\n13. Likely to require the use of monopolar cau Likely to require the use of monopolar cautery, radiofrequency (RF) procedures, external defibrillation, lithotripsy, radiation therapy or transcranial stimulation.tery, radiofrequency (RF) procedures, external defibrillation, lithotripsy, radiation therapy or transcranial stimulation.\n14. Currently on any anticoagulant medications that cannot be discontinued during perioperative period.\n15. Currently exhibiting secondary Parkinsonism due to prescribed medications.\n16. Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints.\n17. Any terminal illness with life expectancy of \\\u003C 1 year.\n18. Any unresolved infection, a coagulopathy or significant cardiac or other medical risk factor for surgery\n19. Current or future risk of being immunocompromised that might significantly increase risk of infection.\n20. Participation in any other clinical trial (e.g. drug, device, or biologics) concurrently or within the preceding 30 days. Participation in any other study will be allowed per investigator\u002Fsponsor discretion only.\n21. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.\n22. Preoperative DBS plan failed to implant STN and GPi. nuclei.(Usually limited by individual anatomical differences)\n23. Preoperative CT scan of the head revealed calcification of the GPI.","22 Years",{"count":108,"type":21},86,[24],"The primary objective of this prospective, multicenter, double-blind, randomized, crossover clinical trial is to evaluate whether Subthalamic Nucleus-Deep Brain Stimulation (STN-DBS) is more effective than Globus Pallidus Internus-Deep Brain Stimulation (GPi-DBS) in improving motor symptoms of patients with Parkinson's disease at 90 days post-treatment.",[27],[113,114,115,116],"Parkinson's disease(PD)","Deep Brain Stimulation(DBS)","Subthalamic Nucleus(STN)","Globus Pallidus Internus(GPi)","2025-11-18",{"date":119,"type":41},"2025-11-26",{"date":121,"type":21},"2025-11-24",{"date":123,"type":21},"2027-06-30",{"name":125,"class":126},"Zhang Jianguo","OTHER_GOV",8,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":18,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":49},"100553144","phase-1-transplantation-of-human-ips-cell-derived-dopaminergic-progenitors-ct1-dap001-for-parkinsons-disease-phase-iii-100553144","NCT06482268","Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I\u002FII)","An Investigator-initiated Clinical Trial of Safety and Efficacy of Transplantation of Human Induced Pluripotent Stem Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I\u002FII)","CT1-DAP001","Inclusion Criteria:\n\n1. The subject has a diagnosis of PD (clinically established or clinically probable) in accordance with the MDS Clinical Diagnostic Criteria for Parkinson's Disease (2015).\n2. The subject has an inadequate response to drug treatments.\n3. The subject is ≥ 40 years and ≤ 75 years of age at the time of informed consent.\n4. The subject has had PD for at least 5 years.\n5. The subject has both ON and OFF (as demonstrated by the MDS-UPDRS Part III and a symptom diary).\n6. The subject does not have a debilitating dyskinesia score greater than or equal to 3 on the MDS-UPDRS.\n7. The subject is in stage 2 or higher on the Hoehn and Yahr scale at OFF time.\n8. The subject is in stage 3 or lower on the Hoehn and Yahr scale at ON time.\n9. The subject has an L-dopa response of 30% or more without influence of antiparkinsonian drugs.\n10. The subject has the following organ functions as determined by laboratory tests at Screening visit:\n\n    1. Neutrophil count ≥ 2,000\u002FμL\n    2. Platelet count ≥ 5.0 × 104\u002FμL\n    3. AST, ALT ≤ 3.0 × upper limit of normal\n    4. Total bilirubin ≤ 1.5 × upper limit of normal\n    5. eGFR ≥ 60 mL\u002Fmin\u002F1.73 m2 (As part of Creatinine testing, an estimated glomerular filtration rate (mL\u002Fmin\u002F1.73 m2)will be calculated based on the CKD-EPI 2021 equation)\n11. The subject is willing to avoid pregnancy using abstinence, highly effective means of birth control, surgical sterility, or menopause.\n12. The subject is willing to comply with the protocol-required assessments.\n13. The subject provides written informed consent to participate in the study. If the subject cannot sign due to physical constraints, verbal consent may be provided with signature of a Legally Authorized Representative.\n\nExclusion Criteria:\n\n1. The subject has an abnormal brain MRI suggestive of brain pathology other than Parkinson's disease.\n2. Atypical parkinsonism (Parkinsonism-Plus syndrome, secondary parkinsonism, hereditary parkinsonism).\n3. The subject has clinical indication or diagnosis of abnormal immune function.\n4. The subject has been diagnosed with a major neurocognitive disorder such as dementia, or is high risk for this.\n5. The subject has bleeding tendency or abnormal coagulation function as evidenced by platelets \\\u003C50 or PT\u002FPTT \\> 1.5x normal.\n6. The subject is HBs antigen-positive, or HBs antibody- or HBc antibody-positive with evidence of HBV-DNA.\n7. The subject is anti-HIV antibody positive.\n8. The subject is anti-HTLV-1 antibody-positive.\n9. The subject has active infection such as hepatitis C or syphilis (STS\u002FTPHA).\n10. The subject has hypersensitivity or contraindication to tacrolimus, concomitant drugs (e.g., levodopa, carbidopa, MRI contrast), and\u002For their components.\n11. Contraindications to general anesthesia as evaluated by subject matter experts.\n12. The subject has a serious allergy to a component (e.g., gentamicin, component of bovine origin, or component of porcine origin) used in the preparation of the study product.\n13. The subject has any of the following conditions\u002Fdiseases concurrently:\n\n    1. Malignant neoplasm\n    2. Epilepsy\n    3. Psychiatric disease (e.g., uncontrolled anxiety or depression, bipolar disorder, schizophrenia)\n    4. Diabetes mellitus with poorly controlled blood glucose (glycosylated hemoglobin \\> 9.0%, or fasting plasma glucose (FPG) ≥ 200 mg\u002FdL (11.1 mmol\u002FL).\n    5. Other serious concurrent diseases (e.g., cerebrovascular disorder, heart disease, chronic respiratory disease, inadequately controlled hypertension) as determined by the investigator.\n14. The subject has a history of any of the following:\n\n    1. Prior malignancy \\\u003C 5 years prior to Screening. Patients who had prior malignancies within 5 years and in complete remission with expected survival of more than 5 years are not excluded\n    2. Epilepsy\n    3. Cerebral hemorrhage or stroke\n    4. Psychiatric disease (e.g., uncontrolled anxiety or depression, bipolar disorder, schizophrenia)\n    5. Congenital long QT syndrome\n    6. Pallidotomy, thalamotomy, or Deep Brain Stimulation\n15. The subject is pregnant or lactating or does not agree to avoid pregnancy throughout the study.\n16. The subject has undergone transplantation of human iPSC-derived dopaminergic progenitors.\n17. The subject, in the opinion of the investigator or sub investigator, is not appropriate to conduct the study safely.","40 Years",{"count":138,"type":21},7,[140],"PHASE1","To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease",[27],[34,144,145,146,35,147,148,149,150,151,152,153,154],"Ataxia","Dopaminergic","Dyskinesia","Neurodegenerative Disease","Brain Disease","CNS","Movement Disorder","Central Nervous System Disease","FDOPA","MRI","Corpus striatum","2025-01-27",{"date":157,"type":41},"2025-01-29",{"date":159,"type":41},"2024-06-01",{"date":161,"type":21},"2028-05",{"name":163,"class":48},"University of California, San Diego",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":172,"targetDuration":174,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":49},"100555991","freezing-of-gait---clinical-outcomes-assessment-100555991","NCT06519279","Freezing of Gait - Clinical Outcomes Assessment","An International Multimodal Protocol for Assessing Freezing of Gait in Individuals Living with Parkinson's Disease","FOG-COA","Inclusion Criteria:\n\n1. Diagnosis of idiopathic Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;\n2. Able to walk independently for a distance of 10 meters, without walking aid;\n3. Absence of a Deep Brain Stimulator;\n4. Stable PD treatment in the 4 weeks prior to participation that is not expected to change in the course of the study.\n5. For patients with FOG: a score of ≥ 1 on the New Freezing Of Gait Questionnaire (NFOG-Q).\n\nExclusion Criteria:\n\n1. Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \\>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait.\n2. Unwilling to temporarily delay the morning anti-Parkinsonian medication.\n3. Preganacy and",{"count":173,"type":21},20,"1 Month","OBSERVATIONAL","To develop a reliable and accurate clinician-reported outcome (ClinRO) measure (against a new and precise definition) and patient reported outcome (PRO) for use by clinicians and researchers to quantify the severity of Freezing of Gait (FOG).",[27],"2025-01-23",{"date":180,"type":41},"2025-01-28",{"date":182,"type":41},"2024-10-01",{"date":184,"type":21},"2025-12",{"name":186,"class":126},"Tel-Aviv Sourasky Medical Center",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":49},"100562109","pas-balance-training-for-parkinson-disease-pd-100562109","NCT06598891","PAS Balance Training for Parkinson Disease (PD)","Effect of Combined PAS Balance Training on Individuals With PD","Inclusion Criteria:\n\n\\- Clinical diagnosis of Parkinson disease.\n\nExclusion Criteria:\n\n* Musculoskeletal injuries on legs\n* Osteoporosis.\n* Any peripheral or central nervous system injury or disease patients.","20 Years",{"count":196,"type":21},60,[24],"Gait initiation (GI) difficulty is a common problem in individuals with Parkinson's disease (PD), often linked to impaired anticipatory postural adjustments (APA). Currently, there are no targeted rehabilitation programs designed specifically for GI-related APA in PD patients. Research has shown that while motor learning deficits are common in PD, explicit learning is better preserved than implicit learning. Therefore, a GI-related APA training system using an explicit learning model could be particularly effective for this population.\n\nDuring motor learning, long-term potentiation (LTP) increases the excitability of the primary motor cortex. Paired associative stimulation (PAS) has been demonstrated to induce LTP-like changes in the motor cortex, making it a potential priming method to enhance motor learning. However, the priming effect of PAS targeted at leg muscles and the motor cortex on motor learning related to GI-APA has not been previously studied.\n\nThe objectives of this study are:\n\n1. To investigate the effects of explicit and implicit training on GI-related APA.\n2. To evaluate the priming effect of PAS on GI-related APA training and the associated plasticity changes in the motor cortex.",[27],[201,202,203,204,205],"Gait Initiation","Paired associative stimulation (PAS)","Balance training","Motor learning","Anticipatory postural adjustment (APA)","2024-10-09",{"date":208,"type":41},"2024-10-10",{"date":206,"type":41},{"date":211,"type":21},"2026-05",{"name":213,"class":48},"Chang Gung University",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":221,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":49},"100561901","differential-assessment-of-hypertonia-100561901","NCT06596187","Differential Assessment of Hypertonia","Differential Assessment of Hypertonia Related to CNS Impairment","Health subjects:\n\nExclusion Criteria:\n\n1. Musculoskeletal injuries on legs.\n2. Osteoporosis.\n\nSCI subjects:\n\nInclusion Criteria 1. Participants with chronic spinal cord injury, with injury duration greater than one year.\n\nExclusion Criteria\n\n1. Current musculoskeletal or joint injuries in the lower limbs.\n2. History of central or peripheral neuromuscular diseases.\n3. Presence of a pacemaker.\n4. Current use of antispastic or antidepressant medications.\n5. Current venous thromboembolism or osteoporosis.\n6. Impairment of the soleus H-reflex arc.\n\nPD subjects:\n\nInclusion Criteria:\n\n\\- Clinical diagnosis of Parkinson disease.\n\nExclusion Criteria:\n\n1. Musculoskeletal injuries on legs\n2. Osteoporosis.\n3. Any peripheral or central nervous system injury or disease patients.",true,{"count":223,"type":21},45,[24],"Spasticity and rigidity are common symptoms of central nervous system injuries, such as spinal cord injury and Parkinson's disease, and result in distinct patterns of increased resistance during passive joint movements. Spasticity is characterized by a velocity-dependent increase in stretch reflexes, accompanied by exaggerated tendon responses, while rigidity is marked by consistent resistance throughout the range of motion, traditionally considered independent of stretch velocity. However, recent studies suggest that rigidity may also be influenced by stretch velocity. This study aims to investigate muscle tone by examining spasticity, rigidity, and normal muscle function through neural and biomechanical changes. Standard clinical tools, such as the Modified Ashworth Scale and Unified Parkinson's Disease Rating Scale, along with additional assessments like the Myoton and Post-Activation Depression (PAD), will be employed.",[227,27],"SCI - Spinal Cord Injury",[229,230,231,232],"Spasticity","Post activation depression","Passive motion device (CPM)","Rigidity",{"date":234,"type":41},"2024-10-15",{"date":206,"type":41},{"date":237,"type":21},"2026-08",{"name":213,"class":48},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":49},"100562108","ar-gait-training-for-parkinsons-disease-100562108","NCT06598878","AR Gait Training for Parkinson's Disease","Effect of AR Environment Stimulation on Proactive and Reactive Modulation of Gait in Individuals With Parkinson Disease",{"count":196,"type":21},[24],"Gait disorders in Parkinson's disease (PD), particularly in complex environments or under stress, present challenges for accurate evaluation and classification, such as in cases of freezing of gait. Traditional clinical and laboratory settings often fail to replicate the complexity needed for precise classification, making effective rehabilitation difficult. This study aims to address these challenges by developing an augmented reality (AR)-based environment that mimics real-world stressors and dynamically adapts to the patient's condition. The AR system is designed to facilitate individualized gait training and rehabilitation by modifying environmental difficulty based on real-time feedback from gait performance and stress levels.\n\nBuilding on Gentile's taxonomy of tasks, the investigators have incorporated PD-specific factors, such as cognitive dual tasks, into our environment classification system. Preliminary results suggest that this system effectively elicits varying gait and heart rate variability (HRV) responses, indicating different stress levels.\n\nThis trial will further test the AR environment's ability to classify patients based on their responses to complex, interactive environments, while also investigating the effects of adaptive AR-based gait training on both gait and stress management in individuals with PD.",[27],[250,251,252],"Augmented Reality","Gait Taining","Heart Rate Variability (HRV)","2024-10-04",{"date":255,"type":41},"2024-10-08",{"date":253,"type":41},{"date":258,"type":21},"2026-07",{"name":213,"class":48},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":268,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":283,"locationsCount":49},"100557857","esketamine-in-microelectrode-recording-guided-subthalamic-deep-brain-stimulation-for-parkinsons-disease-100557857","NCT06543563","Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease","Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease（ASPIRE）：A Randomized Controlled, Double-blind Study","ASPIRE","Inclusion Criteria:\n\n1.50-80 years old, ASA grade II-III; 2.Bilateral STN-DBS of patients with Parkinson's disease; 3.Signed informed consent.\n\nExclusion Criteria:\n\n1. Obstructive sleep apnea;\n2. BMI \\> 30kg\u002Fm2;\n3. Estimated difficult airway;\n4. Severe preoperative anxiety;\n5. Serious dysfunction of important organs (i.e. heart failure, renal or liver dysfunction)\n6. A history of allergy to the anaesthetics.","50 Years","80 Years",{"count":271,"type":21},102,[24],"Under regional anesthesia, subthalamic nucleus deep brain stimulation (STN-DBS) has proven to be an effective therapeutic approach for improving motor symptoms in Parkinson's disease. However, a significant portion of Parkinson's disease (PD) patients is unable to cooperate with the surgery, necessitating the use of awake sedation. Nevertheless, the administration of anesthetic drugs often impacts the electrical signals recorded by microelectrodes to varying degrees. This study is designed as a prospective, randomized, placebo-controlled, double-blind, two-arm investigation. PD patients scheduled for bilateral STN-DBS surgery will be randomly assigned to either the Dexmedetomidine group or the Dexmedetomidine combined with Esketamine group. The differences in neural activity between the two groups will be assessed using the normalized root mean square (NRMS) method. The primary outcome measure is NRMS, while secondary outcome measures include differences in beta oscillation power spectrum analysis, postoperative delirium incidence, postoperative changes in sleep disturbances, postoperative depression, anxiety status, and occurrence of adverse events.",[27,275,276],"Deep Brain Stimulation","Esketamine","2024-08-04",{"date":279,"type":41},"2024-08-09",{"date":279,"type":21},{"date":282,"type":21},"2026-01-31",{"name":284,"class":48},"Beijing Tiantan Hospital",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":268,"maxAge":269,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":49},"100481569","choice-of-anesthesia-in-microelectrode-recording-guided-deep-brain-stimulation-for-parkinsons-disease-100481569","NCT05550714","Choice of Anesthesia in Microelectrode Recording Guided Deep Brain Stimulation for Parkinson's Disease","Choice of Anesthesia in Microelectrode Recording Guided Deep Brain Stimulation for Parkinson's Disease (CHAMPION)：A Randomized Controlled, Non-Inferiority Study","CHAMPION",{"count":293,"type":21},188,[24],"Subthalamic nucleus (STN)-deep brain stimulation (DBS) under general anesthesia has been applied to PD patients who cannot tolerate awake surgery, but general anesthesia will affect the electrical signal in microelectrode recording (MER) to some degree. This study is a prospective randomized controlled, noninferiority study, open label, endpoint outcome evaluator blinded, two-arm study. Parkinson's disease patients undergoing STN-DBS are randomly divided into a conscious sedation group (dexmedetomidine) and a general anesthesia group (desflurane). Normalized root mean square (NRMS) is used to compare the difference of neuronal activity between the two groups. The primary outcome is the percentage of high NRMS recorded by the MER signal (with the average NRMS recorded by MER after entering the STN greater than 2.0). The secondary outcomes are the NRMS, length of the STN, number of MER tracks, and differences in clinical outcomes 6 months after the operation.",[27,297,298,275],"Dexmedetomidine","Desflurane","2024-07-30",{"date":301,"type":41},"2024-08-01",{"date":303,"type":41},"2022-10-15",{"date":305,"type":21},"2024-09-30",{"name":284,"class":48},{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":269,"enrollmentInfo":313,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":315,"conditions":316,"keywords":317,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":49},"100508024","effects-of-propofol-on-brain-function-in-patients-with-parkinsons-disease-100508024","NCT05895019","Effects of Propofol on Brain Function in Patients With Parkinson's Disease","Inclusion Criteria:\n\nPD group:\n\n1. age 18-80 years, ASA class I-III, proposed bilateral DBS surgery;\n2. primary PD, or hereditary PD, various genotypes of PD, responding well to compounded levodopa;\n3. informed consent obtained;\n\nNon-PD group:\n\n1. age 18-80 years, ASA class I-III, proposed non-neurosurgical non-cardiac surgery;\n2. no previous clearly diagnosed neurological disease or neurological dysfunction;\n3. informed consent obtained.\n\nExclusion Criteria:\n\n1. Obstructive sleep apnea;\n2. BMI \\> 30kg\u002Fm2;\n3. Estimated difficult airway;\n4. Patients with prior allergy to anesthetic drugs;\n5. Serious dysfunction of important organs (i.e. heart failure, renal or liver dysfunction);\n6. Patients with craniocerebral trauma or craniocerebral operation history resulting in incomplete skull or brain parenchyma defect;\n7. Patients with alcohol or drug addiction.",{"count":314,"type":21},600,"Propofol is a short-acting general anesthetic drug commonly used in clinical practice, with rapid clinical onset of action, amnesic, anxiolytic, antiepileptic, and muscle relaxant effects. The lack of natural antioxidants in patients with Parkinson's disease and propofol's ability to protect the brain by inhibiting oxidative stress, its pharmacokinetic and pharmacodynamic properties make propofol a suitable anesthetic drug for functional stereotactic surgery in patients with Parkinson's disease. However, changes in brain functional status during propofol anesthesia in Parkinson's patients are unknown. There is a lack of data from extensive clinical studies to support the need for propofol dosing during induction of anesthesia compared with non-Parkinson patients. This study is a prospective cohort study designed to compare the differences in propofol dosing requirements during induction of propofol anesthesia in patients with PD versus non-PD and to monitor the characteristics of altered brain functional status such as EEG and cerebral blood flow autoregulation capacity in PD versus non-PD patients during the perioperative period.",[27],[318,319,320],"Propofol","Electroencephalography","Cerebral autoregulation","2023-06-25",{"date":323,"type":41},"2023-06-27",{"date":325,"type":41},"2023-06-01",{"date":327,"type":21},"2026-09-30",{"name":284,"class":48}]